Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869302 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL31030093 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL2322722 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL16223981 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL31030092 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL2322732 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL2329044 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL22426199 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL22231243 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL5012986 | 0.91 | ACE (0.43) | BRD4MAPTMMEACETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023100110-A1 | PROCESS FOR PREPARING BRIVARACETAM | MACFARLAN SMITH LIMITED (GB) | 2023-06-08 | — | — | WO | claimed |
| CN-111579706-B | Method for detecting hydrolysis impurities of brivaracetam | 宜宾市南溪区红光制药有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115806519-A | Method for splitting intermediate of brivaracetam and application of intermediate | 浙江普洛家园药业有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-111579706-A | Detection method of impurities in hydrolysis of brivaracetam | 宜宾市南溪区红光制药有限公司 | 2020-08-25 | — | — | CN | claimed |
| CN-116041240-B | Asymmetric catalytic hydrogenation synthesis method of brivaracetam intermediate | 扬州奥锐特药业有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11884623-B2 | Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam | DIVI'S LABORATORIES LTD. (IN) | 2024-01-30 | — | — | US | disclosed |
| EP-4282971-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (R )-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | Divi's Laboratories Limited (IN) | 2023-11-29 | — | — | EP | disclosed |
| CN-112154140-B | Compound and application thereof in synthesizing Brivaracetam (Brivaracetam) bulk drug | 福建海西新药创制股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230373914-A1 | PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | DIVI'S LABORATORIES LTD. (IN) | 2023-11-23 | — | — | US | disclosed |
| EP-4036244-B1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (2S)-2-[(4R)-2-OXO-4-PROPYL-PYRROLIDIN-1-YL]BUTYRIC ACID AND ITS CONVERSION INTO BRIVARACETAM | DIVIS LABORATORIES LTD (IN) | 2023-10-11 | — | — | EP | disclosed |
| EP-4036244-B1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (2S)-2-[(4R)-2-OXO-4-PROPYL-PYRROLIDIN-1-YL]BUTYRIC ACID AND ITS CONVERSION INTO BRIVARACETAM | DIVIS LABORATORIES LTD (IN) | 2023-10-11 | — | — | EP | disclosed |
| US-20230174478-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2023-06-08 | — | — | US | disclosed |
| WO-2021120134-A1 | FLUOROACETATE DEHALOGENASE MUTANT AND APPLICATION THEREOF | 弈柯莱生物科技(上海)股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| CN-112955430-A | Preparation method of brivaracetam and intermediate thereof | 浙江华海药业股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-112154140-A | Compound and application thereof in synthesizing bulk drug of Brivaracetam (Brivaracetam) | 福建海西新药创制有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-111579706-A | Detection method of impurities in hydrolysis of brivaracetam | 宜宾市南溪区红光制药有限公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-111579706-A | Detection method of impurities in hydrolysis of brivaracetam | 宜宾市南溪区红光制药有限公司 | 2020-08-25 | — | — | CN | disclosed |
| WO-2020148731-A1 | PROCESS FOR PREPARATION OF BRIVARACETAM INTERMEDIATES AND USE THEREOF | STEREOKEM PVT. LTD. (IN) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020125536-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | 浙江华海药业股份有限公司 | 2020-06-25 | — | — | WO | disclosed |
| CN-108658831-A | The preparation method of 2- OXo-1-pyrrolidine derivatives or its salt | 江苏豪森药业集团有限公司 | 2018-10-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884623-B2 | Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam | BPGM, MGAM, HPD | BRD4 452/4885MAPT 3064/4885MME 1162/4885 |
| US-20230373914-A1 | PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | BPGM, MGAM, HPD | BRD4 452/4885MAPT 3064/4885MME 1162/4885 |
| US-20230174478-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | BLVRB, GABBR2, CCKBR | BRD4 306/4885MAPT 4126/4885MME 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.